WHAT WE DO

Interface Biologics develops transformative biomedical polymer technologies that enhance the safety and effectiveness of implantable medical devices by reducing thrombosis, inhibiting infection and providing programmable delivery of pharmaceuticals.

Founded in 2001, Interface Biologics Inc. is a spin out from the University of Toronto and the groundbreaking work of Professor Paul Santerre, who continues to be actively involved in the company as Chief Scientific Officer.

INVESTORS

IBI has raised over $30M in venture capital financing from the Business Development Bank of Canada (BDC), Covington Venture Partners, the MaRS Investment Accelerator Fund and DSM Venturing.

Covington Logo

COVINGTON CAPITAL

One of Canada's largest providers of venture capital investment funds. Managing over $400 million in assets, Covington provides Canadians with the ability to access venture capital investment opportunities via their suite of retail venture capital product offerings.

DSM Logo

DSM VENTURING

DSM Venturing is an active investor in DSM’s strategic growth fields including Human Nutrition, Biomedical and Solar. DSM Venturing's mission is to explore and take positions in emerging companies in these strategic growth fields in order to create options for DSM and create value.

bdc logo

BUSINESS DEVELOPMENT BANK OF CANADA

A major venture capital investor in Canada, active at every stage of the company's development cycle, from seed through expansion, with a focus on technology-based businesses that have high growth potential and that are positioned to become dominant players in their markets.

MaRS Logo

INVESTMENT ACCELERATOR FUND

Funded by the Province of Ontario, the IAF is a seed fund that assists emerging Ontario technology companies to bring their products and services to market. The fund provides a comprehensive platform of resources, people, connections and funding that entrepreneurs and innovators can access to launch their new ventures.

Powered by Innovasium